Moderna, Inc. 10-Q Summary: Q2 2024
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2024. Moderna, Inc. is a biotechnology company developing mRNA medicines. The company currently has two approved commercial products: the COVID-19 vaccine (Spikevax) and the respiratory syncytial virus (RSV) vaccine (mRESVIA), which received FDA approval in May 2024. The business is transitioning from pandemic-era government supply agreements to a seasonal commercial market model.
Key Financial Metrics
| Metric | Q2 2024 | Q2 2023 | YTD 2024 | YTD 2023 |
|---|---|---|---|---|
| Total Revenue | $241 million | $344 million | $408 million | $2,206 million |
| Net Product Sales | $184 million | $293 million | $351 million | $2,121 million |
| Net Loss | $(1,279) million | $(1,380) million | $(2,454) million | $(1,301) million |
| Net Loss Per Share | $(3.33) | $(3.62) | $(6.41) | $(3.39) |
| Operating Cash Flow (YTD) | $(2,263) million | $(2,140) million | — | — |
| Cash & Investments (Total) | $10,814 million | — | — | — |
| Working Capital | $7,298 million | — | — | — |
Note: All figures in millions except per share data.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 30% in Q2 and 82% YTD compared to 2023. This is primarily due to the transition of the COVID-19 vaccine market to a seasonal commercial model, resulting in lower demand in the first half of the year compared to the prior year's government supply deliveries.
- Cost of Sales Reduction: Cost of sales dropped 84% in Q2 and 86% YTD. The significant decrease is driven by reduced inventory write-downs (from $464 million in Q2 2023 to $14 million in Q2 2024) and lower losses on firm purchase commitments.
- Operating Expenses: Research and development (R&D) expenses increased 6% in Q2 due to personnel costs and the purchase of a priority review voucher, partially offset by lower clinical trial spending. Selling, general, and administrative (SG&A) expenses decreased 19% due to reduced consulting fees.
- Liquidity: Total cash, cash equivalents, and investments decreased by approximately $2.5 billion from year-end 2023, primarily due to operating cash outflows and capital expenditures.
Guidance, Outlook, and Risks
- Seasonality: Management anticipates higher demand for COVID-19 vaccines in the fall and winter seasons. Full-year 2024 net product sales are expected to be lower than 2023 levels due to the seasonal commercial market shift.
- Cost Outlook: Full-year 2024 cost of sales as a percentage of net product sales is expected to be lower than the 70% experienced in 2023, driven by manufacturing efficiency and reduced write-downs.
- RSV Commercialization: Sales of the newly approved RSV vaccine (mRESVIA) have not yet commenced as of June 30, 2024, though regulatory approvals are being pursued globally.
- Pipeline Progress: Positive Phase 3 data announced for the next-generation COVID-19 vaccine (mRNA-1283) and the combination flu/COVID vaccine (mRNA-1083). Continued progress in the individualized neoantigen therapy (INT) program with Merck.
- Risks: Key risks include the uncertainty of the seasonal commercial market for COVID-19 vaccines, potential inventory obsolescence, reliance on third-party manufacturing, and ongoing intellectual property litigation (specifically against Pfizer/BioNTech).
Investor Verification Checklist
- RSV Sales Timeline: Verify the expected start date for mRESVIA commercial sales and initial demand projections.
- Seasonal Demand: Monitor Q3 and Q4 COVID-19 vaccine sales volumes to confirm the anticipated seasonal rebound.
- Inventory Valuation: Review future inventory write-down risks given the $399 million inventory balance and the transition to new vaccine strains (KP.2/JN.1).
- Capital Expenditures: Assess the impact of ongoing manufacturing build-out and the $378 million in CapEx incurred YTD on future cash burn.
- Legal Proceedings: Track the status of the patent infringement litigation against Pfizer and BioNTech, particularly the appeal of the Dutch court decision.